Bloomberg News

Medicines Co., APP Settle Patent Suits Over Generic Angiomax

January 23, 2012

(Updates with company statement in third paragraph.)

Jan. 23 (Bloomberg) -- Medicines Co. and Fresenius’s APP Pharmaceuticals Inc. settled litigation over patents for the Angiomax anticoagulant drug, with Medicines agreeing to pay $30 million to license some APP drugs.

Medicines Co., based in Parsippany, New Jersey, sued Schaumburg, Illinois-based APP in October 2009 IN Wilmington, Delaware, federal court alleging patent infringement for plans to market a generic copy of Angiomax. APP announced the settlement today.

“The settlement agreement includes a license by The Medicines Co. to APP” to sell generic Angiomax in the U.S. starting May 1, 2019, Medicines said in a statement.

Medicines will pay APP $30 million for a non-exclusive license “to sell 10 specified generic products” to hospitals and suppliers until Jan. 22, 2022, according to a Medicines filing with the U.S. Securities and Exchange Commission.

The case is The Medicines Co. v. APP Pharmaceuticals, 09- CV-00752, U.S. District Court, District of Delaware (Wilmington).

--Editors: Andrew Dunn, Peter Blumberg

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at

To contact the editor responsible for this story: Michael Hytha at

The Aging of Abercrombie & Fitch
blog comments powered by Disqus